PMID- 36910848
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230314
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 18
IP  - 1
DP  - 2023
TI  - HDAC5-mediated PRAME regulates the proliferation, migration, invasion, and EMT of 
      laryngeal squamous cell carcinoma via the PI3K/AKT/mTOR signaling pathway.
PG  - 20230665
LID - 10.1515/med-2023-0665 [doi]
LID - 20230665
AB  - Laryngeal squamous cell carcinoma (LSCC) is an aggressive and lethal malignant 
      neoplasm with extremely poor prognoses. Accumulating evidence has indicated that 
      preferentially expressed antigen in melanoma (PRAME) is correlated with several 
      kinds of cancers. However, there is little direct evidence to substantiate the 
      biological function of PRAME in LSCC. The purpose of the current study is to 
      explore the oncogenic role of PRAME in LSCC. PRAME expression was analyzed in 57 
      pairs of LSCC tumor tissue samples through quantitative real-time PCR, and the 
      correlation between PRAME and clinicopathological features was analyzed. The 
      result indicated that PRAME was overexpressed in the LSCC patients and correlated 
      with the TNM staging and lymphatic metastasis. The biological functions and 
      molecular mechanism of PRAME in LSCC progression were investigated through in 
      vitro and in vivo assays. Functional studies confirmed that PRAME facilitated the 
      proliferation, invasion, migration, and epithelial-mesenchymal transition of LSCC 
      cells, and PRAME also promoted tumor growth in vivo. HDAC5 was identified as an 
      upstream regulator that can affect the expression of PRAME. Moreover, PRAME 
      played the role at least partially by activating PI3K/AKT/mTOR pathways. The 
      above findings elucidate that PRAME may be a valuable oncogene target, 
      contributing to the diagnosis and therapy of LSCC.
CI  - (c) 2023 the author(s), published by De Gruyter.
FAU - Yu, Lei
AU  - Yu L
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Cao, Huan
AU  - Cao H
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Yang, Jian-Wang
AU  - Yang JW
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Meng, Wen-Xia
AU  - Meng WX
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Yang, Chuan
AU  - Yang C
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Wang, Jian-Tao
AU  - Wang JT
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Yu, Miao-Miao
AU  - Yu MM
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
FAU - Wang, Bao-Shan
AU  - Wang BS
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, Hebei, China.
LA  - eng
PT  - Journal Article
DEP - 20230309
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC9999116
OTO - NOTNLM
OT  - HDAC5
OT  - PI3K/AKT/mTOR signaling pathway
OT  - PRAME
OT  - biomarker
OT  - laryngeal squamous cell carcinoma
OT  - prognosis
COIS- Conflict of interest: The authors declare that they have no competing interest.
EDAT- 2023/03/14 06:00
MHDA- 2023/03/14 06:01
PMCR- 2023/03/09
CRDT- 2023/03/13 04:17
PHST- 2022/08/25 00:00 [received]
PHST- 2022/12/29 00:00 [revised]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/03/13 04:17 [entrez]
PHST- 2023/03/14 06:00 [pubmed]
PHST- 2023/03/14 06:01 [medline]
PHST- 2023/03/09 00:00 [pmc-release]
AID - med-2023-0665 [pii]
AID - 10.1515/med-2023-0665 [doi]
PST - epublish
SO  - Open Med (Wars). 2023 Mar 9;18(1):20230665. doi: 10.1515/med-2023-0665. 
      eCollection 2023.